Pathologic Function – Page 2 – Talk Bio

Actionable Insights Powered by AI

Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL

2 months ago talkbio0Tagged Cardiovascular system, heart drug, Inflammation, interleukin-6, Markers (device), Nordisk, pacibekitug, Phase 2 trial, SMPX gene, tourmaline, United States Food and Drug Administration

Tourmaline Bio; heart drug; pacibekitug; cardiovascular inflammation; inflammation markers; Novo Nordisk; CSL; Phase 2 trial; FDA; IL-6

FDA, CDC call for pause of chikungunya shot rollout in older adults

3 months ago talkbio0Tagged Adverse event, Centers for Disease Control and Prevention (U.S.), Chikungunya Fever, concerns, Elderly (population group), Ixchiq vaccine, pause recommendation, Safety, United States Food and Drug Administration

Ixchiq vaccine, chikungunya, safety concerns, older adults, FDA, CDC, pause recommendation, adverse events

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

3 months ago talkbio0Tagged Biosciences, Biotech Layoffs, Collaboration termination, Facility (object), IgM antibodies, Immunoglobulin M, Immunology, Inflammation, Neoplasms, Reparative closure, sanofi

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

3 months ago3 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

Exact Sciences plans ‘transformative year’ with 3 cancer test debuts

3 months ago talkbio0Tagged Exact brand biomedical or dental material, Hypersensitivity, MRD, Science

Science, MRD, Exact brand biomedical or dental material, Hypersensitivity

France pauses chikungunya vaccinations in the elderly after patient death

3 months ago talkbio0Tagged Adverse event, Age, Chikungunya Fever, Disease Outbreaks, Elderly (population group), France, Latex Fixation Tests, older, Reunion Island, Vaccination, Vaccines

Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination

Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly

3 months ago talkbio0Tagged Alzheimer, Apolipoprotein E4, ARIA, authorization, Biogen, Eisai, Eli Lilly, EU, High, Kisunla, Leqembi, Restricted

Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High

: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

4 months ago talkbio0Tagged Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Combined, first-line, United States Food and Drug Administration, Yervoy

United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined

FDA okays Novartis’ second IgA nephropathy therapy Vanrafia

4 months ago talkbio0Tagged Approved, IGA Glomerulonephritis, Novartis, Proteinuria, United States Food and Drug Administration, Vanrafia

Vanrafia, United States Food and Drug Administration, Approved, Novartis, IGA Glomerulonephritis, Proteinuria

Sanofi adds new inflammatory target to growing Nurix tie-up

4 months ago talkbio0Tagged Autoimmune Diseases, cellular targeting, Collaboration, DEL-AI, Inflammation, Nurix, sanofi, STAT6 protein, human, Target, TRANSCRIPTION FACTOR

Nurix, sanofi, Target, STAT6 protein, human, cellular targeting, Collaboration, Inflammation, Autoimmune Diseases, TRANSCRIPTION FACTOR, DEL-AI